Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05315895
Other study ID # SZ2021ZZ06
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 6, 2022
Est. completion date March 30, 2028

Study information

Verified date November 2022
Source Guangzhou University of Traditional Chinese Medicine
Contact Jianwen Guo, MD
Phone +86-13724899379
Email 1308251832@qq.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The researchers plain to build a large-scale, longitudinal, prospective cohort characterized by TCM dampness syndrome. With the biobank of this cohort the investigators want to find the causality between TCM dampness syndrome and clinical chronic diseases and a new way to treat clinical disease.


Description:

DACOS is a national large- scale, longitudinal, multi-center, prospective, cohort study of natural person aged 35 to 75. The baseline survey and the follow-up surveys will be conducted in 5 areas covering the eastern, northern, western, southern and middle parts of China. In this study 100,000 natural person will be regularly followed up for 5 years(visited once a year), with the loss rate ≤15%. Three parts will be carried in the form of interview, physical examination and biological sample collection. During the interview, the investigators plan to do some questionnaires to learn participants' demographic characteristics, life style, disease history, healthy condition(EQ-5D-5L, SDS,), cognition state(AD-8, MMSE, MoCA) and the results of TCM syndrome differentiation(Score of Dampness syndrome and TCM constitution scale). All biological specimens (including blood, feces, urine, saliva and tongue coating) will be collected and stored in the biological resource center until researchers request their use. With the building up of this cohort, the researchers will analyze the causality between dampness syndrome and specific chronic diseases such as diabetes, coronary heart disease, cancer, dementia and so on.


Recruitment information / eligibility

Status Recruiting
Enrollment 100000
Est. completion date March 30, 2028
Est. primary completion date December 30, 2027
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 35 Years to 79 Years
Eligibility Inclusion Criteria: 1. Residents aged 30 to 79, whose residence is consistent with their registered permanent residence location; 2. Residents who voluntarily participate in the project, agree to the collection of their biological information, and sign the informed consent form; 3. Residents who have no mental illness and other related diseases, and display a normal ability of expression and understanding; Exclusion Criteria: 1. Residents who reject collaboration; 2. Residents who allow no follow-up visits.

Study Design


Intervention

Other:
natural aging process
To observe the relationship between new cases of diseases and health status of people exposed to different factors such as life style, alcohol consumption, eating habits, etc.

Locations

Country Name City State
China Guangdong Province Hospital of Tradtional Chinese Medicine Guangzhou Guangdong

Sponsors (2)

Lead Sponsor Collaborator
Guangzhou University of Traditional Chinese Medicine State Key Laboratory of Dampness Syndrome of Chinese Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary emerging diseases This study will pay attention to the emerging situation of clinical chronic diseases, such as cancer, diabetes, hypertension, coronary heart disease, dementia, etc. Each follow-up the researchers will record the incidence of the emerging diseases of interviewees' by questionnaire including the name of the disease, time of onset and treatments. through study completion, an average of 1 year
Secondary Montreal Cognitive Assessment(MoCA) MoCA is a brief, 30-question test that helps healthcare professionals detect cognitive impairments very early on, allowing for faster diagnosis and patient care. MoCA is the most sensitive test available for detecting Alzheimer's disease, measuring executive functions and multiple cognitive domains. The value range 0-30: higher scores mean a better Cognitine. The score above 26 is considered the normal congnitive level through study completion, an average of 1 year
Secondary European Quality of Life 5-dimensional questionnaire (EQ-5D-5L) The EQ-5D comprises five dimensions of health: mobility, ability to self-care, ability to undertake usual activities, pain and discomfort, and anxiety and depression. . EQ-5D-5L, includes five levels of severity for each dimension (no problems, slight problems, moderate problems, severe problems, and extreme problems). The value range 0-100: higher scores mean a worse outcome. through study completion, an average of 1 year
Secondary Mini-Mental State Exam (MMSE) MMSE is a widely used test of cognitive function among the elderly; it includes tests of orientation, attention, memory, language and visual-spatial skills. The value range 0-30: higher scores mean a better Cognitine. through study completion, an average of 1 year
Secondary interview questionnaire Demographic characteristic, life style. disease history, allergies will be involoved. through study completion, an average of 1 year
Secondary change of the blood routine results WBC, RBC, PLT , HB, NEUT% and LYM% will be tested and recorded. Above or below each mormal value will be considered as abnormal. through study completion, an average of 1 year
Secondary urine routine urinary WBC and urinary RBC will be observed. negative or below 5/HP is normal.
BLO and GLU and PRO in urine will also be test. Negative is normal.
through study completion, an average of 1 year
Secondary change of faeces routine cells in faeces will be tested such as RBC and WBC. Negative occult blood(FOB) is difined normal. through study completion, an average of 1 year
Secondary change of hepatic function The researchers will check the results of ALT and AST. TBil, DBIL, TBA and TP, ALB. Any indices above or below the criteria range is defined as abnormal. Every time point investigators will record the change of these indices. an average of 1 year
Secondary change of renal function The researchers will check the results of Cr, BUN, TC, LDL, HDL,UA and fasting blood glucose,glycosylanted. Any indices above or below the criteria range is defined as abnormal. Every time point investigators will record the change of these indices. an average of 1 year
Secondary change of CRP change of CPP an average of 1 year
Secondary change of Hcy change of Hcy an average of 1 year
Secondary change of thyroid function change of TSH ,FT3, FT4 an average of 1 year
Secondary change of Vit B12 and folic acid change of Vit B12 an average of 1 year
Secondary change of coagulation function change of PT, INR,TT,APTT,FIB an average of 1 year
Secondary change of abdominal ultrasound change of abdominal ultrasound an average of 1 year
Secondary change of gynecologic ultrasound change of gynecologic ultrasound an average of 1 year
Secondary change of ECG The researchers will check the change of P, QRS and ST segments separately in electrocardiogram. an average of 1 year
Secondary change of brain MRI change of brain MRI. The investigators will focus on the change of hippocampal volume and the spacing of temporal sulcus gyrus. an average of 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients